10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.622.0609

BIRC3 Antibody (N-term) Blocking peptide

Synthetic peptide
Catalog # BP14020a

Specification

BIRC3 Antibody (N-term) Blocking peptide - Product Information

Primary Accession Q13489

BIRC3 Antibody (N-term) Blocking peptide - Additional Information

Gene ID 330

Other Names
Baculoviral IAP repeat-containing protein 3, 632-, Apoptosis inhibitor 2, API2, C-IAP2, IAP homolog C, Inhibitor of apoptosis protein 1, IAP-1, hIAP-1, hIAP1, RING finger protein 49, TNFR2-TRAF-signaling complex protein 1, BIRC3, API2, IAP1, MIHC, RNF49

Target/Specificity
The synthetic peptide sequence used to generate the antibody AP14020a was selected from the N-term region of BIRC3. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

Format
Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Storage
Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions
This product is for research use only. Not for use in diagnostic or therapeutic procedures.

BIRC3 Antibody (N-term) Blocking peptide - Protein Information

Name BIRC3

BIRC3 Antibody (N-term) Blocking peptide - Background

The protein encoded by this gene is a member of a familyof proteins that inhibits apoptosis by binding to tumor necrosisfactor receptor-associated factors TRAF1 and TRAF2, probably byinterfering with activation of ICE-like proteases. The encodedprotein inhibits apoptosis induced by serum deprivation but doesnot affect apoptosis resulting from exposure to menadione, a potentinducer of free radicals. The amino acid sequence predicts threebaculovirus IAP repeat domains and a ring finger domain. Transcriptvariants encoding the same isoform have been identified. [providedby RefSeq].

BIRC3 Antibody (N-term) Blocking peptide - References

Zane, L., et al. Virology 407(2):341-351(2010)Bailey, S.D., et al. Diabetes Care 33(10):2250-2253(2010)Kim, C.W., et al. Biochem. Biophys. Res. Commun. 400(1):46-52(2010)Petersen, S.L., et al. Proc. Natl. Acad. Sci. U.S.A. 107(26):11936-11941(2010)Friboulet, L., et al. BMC Cancer 10, 327 (2010) :

Synonyms API2, MIHC, RNF49

Function
Multi-functional protein which regulates not only caspases and apoptosis, but also modulates inflammatory signaling and immunity, mitogenic kinase signaling and cell proliferation, as well as cell invasion and metastasis. Acts as an E3 ubiquitin-protein ligase regulating NF-kappa-B signaling and regulates both canonical and non- canonical NF-kappa-B signaling by acting in opposite directions: acts as a positive regulator of the canonical pathway and suppresses constitutive activation of non-canonical NF-kappa-B signaling. The target proteins for its E3 ubiquitin-protein ligase activity include: RIPK1, RIPK2, RIPK3, RIPK4, CASP3, CASP7, CASP8, IKBKE, TRAF1, and BCL10. Acts as an important regulator of innate immune signaling via regulation of Toll-like receptors (TLRs), Nodlike receptors (NLRs) and RIG-I like receptors (RLRs), collectively referred to as pattern recognition receptors (PRRs). Protects cells from spontaneous formation of the ripoptosome, a large multi-protein complex that has the capability to kill cancer cells in a caspase-dependent and caspase- independent manner. Suppresses ripoptosome formation by ubiquitinating RIPK1 and CASP8.

Cellular Location
Cytoplasm. Nucleus

Tissue Location
Highly expressed in fetal lung, and kidney. In the adult, expression is mainly seen in lymphoid tissues, including spleen, thymus and peripheral blood lymphocytes

BIRC3 Antibody (N-term) Blocking peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.

- Blocking Peptides